Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Trial Profile

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs Copanlisib (Primary)
  • Indications Anaplastic large cell lymphoma; B cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms CHRONOS-1
  • Sponsors Bayer
  • Most Recent Events

    • 17 Jun 2018 Results (n=20) assessing the efficacy and safety of copanlisib treatment in indolent lymphoma patients with a medical history of diabetes mellitus, presented at the 23rd Congress of the European Haematology Association.
    • 05 Jun 2018 Results assessing Copanlisib treatment in a subgroup of patients with Diabetes Mellitus (n=20) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 12 Dec 2017 Results of subset analysis (n=23) assessing efficacy of Copanlisib monotherapy in marginal zone lymphoma patients from this trial, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top